Publications — EMulate Therapeutics

Publications

Tubulin polymerization effect of anti-cancer signals, a proof of concept

A low power, specific, digital radio frequency energy signal is capable of promoting tubulin polymerization as effectively as a commercially available taxane.
Increasing lipid production in algae using signals derived from genetic materials shows promising effect

A low power, specific, digital radio frequency energy signal derived from siRNA is shown to reduce the mRNA levels in algae of the enzyme MAA7 up to 50% compared with untreated controls.
Treating adult recurrent glioblastoma patients with EMulates therapeutic medical device, data from feasibility study

An early feasibility study of EMulate’s (formerly Nativis) Voyager device in patients with recurrent glioblastoma: first cohort in US
Effects of Magnetic Fields on Biological Systems – An Overview

An overview of literature pertaining to EMF and biological systems, and a review of data in ultra-low RFE
A feasibility study of the EMulate Voyager® device in patients with recurrent glioblastoma in Australia

Evaluation of the Nativis Voyager® as monotherapy for recurrent glioblastoma (rGBM)
EMulate technology: a third-party overview

A lay-persons’ explanation of EMulate (formerly Nativis) technology and potential impacts
Precision knockdown of EGFR gene expression using radio frequency electromagnetic energy

Signals derived from siRNA are applied in an EGFR assay and show statistically significant effect
Psychology Today: a possible role for electromagnetic therapy in mental health

Precise electromagnetic fields, like those created by EMulate Therapeutics, could expand treatment options in mental health
Positive pre-clinical results of EMulate’s pain-treating signals in validated animal studies

Signals derived from proven pain-treating drugs show statistically significant results in several pain categories.
Tubulin Polymerization Rates Produced by EMulate Therapeutics’ Anti-Cancer ulRFE® Derived from Paclitaxel as Compared to Known Clinical Concentrations of Paclitaxel (Cremaphor/EL Suspension)

Tubulin Polymerization Rates Produced by EMulate Therapeutics’ Anti-Cancer ulRFE® Derived from Paclitaxel as Compared to Known Clinical Concentrations of Paclitaxel (Cremaphor/EL Suspension